SAO PAULO, (Reuters) - The coronavirus vaccine developed by China’s Sinovac Biotech showed a general efficacy of less than 60% in its late-stage trial in Brazil, a news website reported yesterday, citing two people who seen the results.
The article Sinovac’s vaccine efficacy less than 60% in Brazil trial -report appeared first on Stabroek News.
